不确定潜能克隆造血与神经退行性疾病的风险

IF 9 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Journal of Internal Medicine Pub Date : 2024-07-29 DOI:10.1111/joim.20001
Xinyuan Liu, Huiwen Xue, Karin Wirdefeldt, Huan Song, Karin Smedby, Fang Fang, Qianwei Liu
{"title":"不确定潜能克隆造血与神经退行性疾病的风险","authors":"Xinyuan Liu,&nbsp;Huiwen Xue,&nbsp;Karin Wirdefeldt,&nbsp;Huan Song,&nbsp;Karin Smedby,&nbsp;Fang Fang,&nbsp;Qianwei Liu","doi":"10.1111/joim.20001","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Little is known regarding the association between clonal hematopoiesis of indeterminate potential (CHIP) and risk of neurodegenerative diseases.</p>\n </section>\n \n <section>\n \n <h3> Objective</h3>\n \n <p>To estimate the risk of neurodegenerative diseases among individuals with CHIP.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We conducted a community-based cohort study based on UK Biobank and used Cox regression to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for the risk of any neurodegenerative disease, subtypes of neurodegenerative diseases (including primary neurodegenerative diseases, vascular neurodegenerative diseases, and other neurodegenerative diseases), and specific diagnoses of neurodegenerative diseases (i.e., amyotrophic lateral sclerosis [ALS], Alzheimer's disease [AD], and Parkinson's disease [PD]) associated with CHIP.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>We identified 14,440 individuals with CHIP and 450,907 individuals without CHIP. Individuals with CHIP had an increased risk of any neurodegenerative disease (HR 1.10, 95% CI: 1.01–1.19). We also observed a statistically significantly increased risk for vascular neurodegenerative diseases (HR 1.31, 95% CI 1.05–1.63) and ALS (HR 1.50, 95% CI 1.05–2.15). An increased risk was also noted for other neurodegenerative diseases (HR 1.13, 95% CI 0.97–1.32), although not statistically significant. Null association was noted for primary neurodegenerative diseases (HR 1.06, 95% CI 0.96–1.17), AD (HR 1.04, 95% CI 0.88–1.23), and PD (HR 1.02, 95% CI 0.86–1.21). The risk increase in any neurodegenerative disease was mainly observed for <i>DNMT3A</i>-mutant CHIP, <i>ASXL1</i>-mutant CHIP, or <i>SRSF2</i>-mutant CHIP.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Individuals with CHIP were at an increased risk of neurodegenerative diseases, primarily vascular neurodegenerative diseases and ALS, but potentially also other neurodegenerative diseases. These findings suggest potential shared mechanisms between CHIP and neurodegenerative diseases.</p>\n </section>\n </div>","PeriodicalId":196,"journal":{"name":"Journal of Internal Medicine","volume":"296 4","pages":"327-335"},"PeriodicalIF":9.0000,"publicationDate":"2024-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Clonal hematopoiesis of indeterminate potential and risk of neurodegenerative diseases\",\"authors\":\"Xinyuan Liu,&nbsp;Huiwen Xue,&nbsp;Karin Wirdefeldt,&nbsp;Huan Song,&nbsp;Karin Smedby,&nbsp;Fang Fang,&nbsp;Qianwei Liu\",\"doi\":\"10.1111/joim.20001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>Little is known regarding the association between clonal hematopoiesis of indeterminate potential (CHIP) and risk of neurodegenerative diseases.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Objective</h3>\\n \\n <p>To estimate the risk of neurodegenerative diseases among individuals with CHIP.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>We conducted a community-based cohort study based on UK Biobank and used Cox regression to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for the risk of any neurodegenerative disease, subtypes of neurodegenerative diseases (including primary neurodegenerative diseases, vascular neurodegenerative diseases, and other neurodegenerative diseases), and specific diagnoses of neurodegenerative diseases (i.e., amyotrophic lateral sclerosis [ALS], Alzheimer's disease [AD], and Parkinson's disease [PD]) associated with CHIP.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>We identified 14,440 individuals with CHIP and 450,907 individuals without CHIP. Individuals with CHIP had an increased risk of any neurodegenerative disease (HR 1.10, 95% CI: 1.01–1.19). We also observed a statistically significantly increased risk for vascular neurodegenerative diseases (HR 1.31, 95% CI 1.05–1.63) and ALS (HR 1.50, 95% CI 1.05–2.15). An increased risk was also noted for other neurodegenerative diseases (HR 1.13, 95% CI 0.97–1.32), although not statistically significant. Null association was noted for primary neurodegenerative diseases (HR 1.06, 95% CI 0.96–1.17), AD (HR 1.04, 95% CI 0.88–1.23), and PD (HR 1.02, 95% CI 0.86–1.21). The risk increase in any neurodegenerative disease was mainly observed for <i>DNMT3A</i>-mutant CHIP, <i>ASXL1</i>-mutant CHIP, or <i>SRSF2</i>-mutant CHIP.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>Individuals with CHIP were at an increased risk of neurodegenerative diseases, primarily vascular neurodegenerative diseases and ALS, but potentially also other neurodegenerative diseases. These findings suggest potential shared mechanisms between CHIP and neurodegenerative diseases.</p>\\n </section>\\n </div>\",\"PeriodicalId\":196,\"journal\":{\"name\":\"Journal of Internal Medicine\",\"volume\":\"296 4\",\"pages\":\"327-335\"},\"PeriodicalIF\":9.0000,\"publicationDate\":\"2024-07-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Internal Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/joim.20001\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Internal Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/joim.20001","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

摘要

背景:人们对不确定潜能克隆造血(CHIP)与神经退行性疾病风险之间的关系知之甚少:人们对不确定潜能克隆造血(CHIP)与神经退行性疾病风险之间的关系知之甚少:目的:估算CHIP患者罹患神经退行性疾病的风险:我们在英国生物数据库的基础上开展了一项社区队列研究,并使用 Cox 回归估算了任何神经退行性疾病、神经退行性疾病亚型(包括原发性神经退行性疾病、血管性神经退行性疾病和其他神经退行性疾病)和特定神经退行性疾病诊断(即:肌萎缩性脊髓侧索硬化症)的危险比(HRs)和 95% 置信区间(CIs)、结果:我们发现了 14,440 名患有 CHIP 的患者和 450,907 名未患有 CHIP 的患者。CHIP患者罹患任何神经退行性疾病的风险都有所增加(HR 1.10,95% CI:1.01-1.19)。我们还发现,血管神经退行性疾病(HR 1.31,95% CI 1.05-1.63)和 ALS(HR 1.50,95% CI 1.05-2.15)的患病风险在统计学上明显增加。其他神经退行性疾病的风险也有所增加(HR 1.13,95% CI 0.97-1.32),但无统计学意义。原发性神经退行性疾病(HR 1.06,95% CI 0.96-1.17)、AD(HR 1.04,95% CI 0.88-1.23)和帕金森病(HR 1.02,95% CI 0.86-1.21)的相关性为零。任何神经退行性疾病的风险增加主要出现在DNMT3A突变型CHIP、ASXL1突变型CHIP或SRSF2突变型CHIP中:结论:CHIP 患者罹患神经退行性疾病(主要是血管神经退行性疾病和渐冻症)的风险增加,但也可能罹患其他神经退行性疾病。这些发现表明,CHIP 与神经退行性疾病之间存在潜在的共同机制。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Clonal hematopoiesis of indeterminate potential and risk of neurodegenerative diseases

Background

Little is known regarding the association between clonal hematopoiesis of indeterminate potential (CHIP) and risk of neurodegenerative diseases.

Objective

To estimate the risk of neurodegenerative diseases among individuals with CHIP.

Methods

We conducted a community-based cohort study based on UK Biobank and used Cox regression to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for the risk of any neurodegenerative disease, subtypes of neurodegenerative diseases (including primary neurodegenerative diseases, vascular neurodegenerative diseases, and other neurodegenerative diseases), and specific diagnoses of neurodegenerative diseases (i.e., amyotrophic lateral sclerosis [ALS], Alzheimer's disease [AD], and Parkinson's disease [PD]) associated with CHIP.

Results

We identified 14,440 individuals with CHIP and 450,907 individuals without CHIP. Individuals with CHIP had an increased risk of any neurodegenerative disease (HR 1.10, 95% CI: 1.01–1.19). We also observed a statistically significantly increased risk for vascular neurodegenerative diseases (HR 1.31, 95% CI 1.05–1.63) and ALS (HR 1.50, 95% CI 1.05–2.15). An increased risk was also noted for other neurodegenerative diseases (HR 1.13, 95% CI 0.97–1.32), although not statistically significant. Null association was noted for primary neurodegenerative diseases (HR 1.06, 95% CI 0.96–1.17), AD (HR 1.04, 95% CI 0.88–1.23), and PD (HR 1.02, 95% CI 0.86–1.21). The risk increase in any neurodegenerative disease was mainly observed for DNMT3A-mutant CHIP, ASXL1-mutant CHIP, or SRSF2-mutant CHIP.

Conclusion

Individuals with CHIP were at an increased risk of neurodegenerative diseases, primarily vascular neurodegenerative diseases and ALS, but potentially also other neurodegenerative diseases. These findings suggest potential shared mechanisms between CHIP and neurodegenerative diseases.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Internal Medicine
Journal of Internal Medicine 医学-医学:内科
CiteScore
22.00
自引率
0.90%
发文量
176
审稿时长
4-8 weeks
期刊介绍: JIM – The Journal of Internal Medicine, in continuous publication since 1863, is an international, peer-reviewed scientific journal. It publishes original work in clinical science, spanning from bench to bedside, encompassing a wide range of internal medicine and its subspecialties. JIM showcases original articles, reviews, brief reports, and research letters in the field of internal medicine.
期刊最新文献
An electronic medical record retrieval system can be used to identify missed diagnosis in patients with primary ciliary dyskinesia. Effects of letrozole therapy in former users of anabolic steroids: A randomized clinical trial. Therapeutic BCG vaccine protects against long COVID: The BATTLE randomized clinical trial. Different ways of diagnosing selective glomerular hypofiltration syndromes such as shrunken pore syndrome and the associated increase in mortality. Statin-associated regulation of hepatic PNPLA3 in patients without known liver disease.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1